# Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

> **NCT04278417** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 689 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **BIOLOGICAL:** Brolucizumab 6 mg
- **PROCEDURE:** Panretinal photocoagulation laser

## Key facts

- **NCT ID:** NCT04278417
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2023-10-30
- **Final completion:** 2024-08-19
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278417, "Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04278417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*